Neurelis Overview

  • Founded
  • 2007
Founded
  • Status
  • Private
  • Employees
  • 135
Employees
  • Latest Deal Type
  • Debt
  • Latest Deal Amount
  • $65M
Latest Deal Amount
  • Investors
  • 7

Neurelis General Information

Description

Developer of technology-enhanced pharmaceutical products designed for the treatment of epilepsy and central nervous system disorders. The company's products assist in drug delivery enhancements that are applicable to a wide range of molecules including therapeutic proteins and peptides and non-peptide large and small molecules, enabling medical professionals to enhance therapeutic benefits and address the unmet needs in patient care.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Primary Office
  • 3430 Carmel Mountain Road
  • Suite 300
  • San Diego, CA 92121
  • United States
+1 (858) 000-0000

Neurelis Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Neurelis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Debt - General 11-Aug-2021 $65M 00000 Completed Generating Revenue
6. Later Stage VC (Series D) 05-Mar-2021 00000 00000 00000 Completed Generating Revenue
5. Later Stage VC (Series C) 06-Oct-2020 000.00 000.00 00000 Completed Generating Revenue
4. Later Stage VC (Series B) 30-Dec-2016 0000 000.00 0000 Completed Clinical Trials - General
3. Later Stage VC (Series A) 02-Jul-2015 0000 000.00 000.00 Completed Product Development
2. Merger/Acquisition 11-Jul-2014 $8.75M 00.000 Cancelled Startup
1. Angel (individual) 30-Sep-2011 $4.5M $4.5M Completed Startup
To view Neurelis’s complete valuation and funding history, request access »

Neurelis Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series D 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series C 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.00
Series B 19,815,059 $0.000100 8% $0.76 $0.76 1x $0.76 13.43%
Series A 37,744,121 $0.000100 8% $0.47 $0.47 1x $0.47 25.58%
To view Neurelis’s complete cap table history, request access »

Neurelis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of technology-enhanced pharmaceutical products designed for the treatment of epilepsy and central nervous syst
Pharmaceuticals
San Diego, CA
135 As of 2021
00000
000000000 00000

0000000

ud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in re
0000 000000000
San Diego, CA
000 As of 0000
00000
00000000000 00000

0000000

rit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidata
0000000000000
London, Canada
00 As of 0000
000.00
00000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Neurelis Competitors (34)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
ViaCyte Venture Capital-Backed San Diego, CA 000 00000 00000000000 00000
0000000 Corporation London, Canada 00 000.00 00000000 000.00
000000 00000000000 Formerly VC-backed San Diego, CA 000 00000 000000&0
000000 (0000 00000 Angel-Backed New York, NY 0 00000 0000000000 00000
0000000 0000000000 Formerly VC-backed Plymouth Meeting, PA 000 00000 00000000 00000
You’re viewing 5 of 34 competitors. Get the full list »

Neurelis Executive Team (8)

Name Title Board Seat Contact Info
Craig Chambliss Co-Founder, Chief Executive Officer, Board Member & President
George Stuart Chief Financial Officer & Senior Vice President
Jenny Alonso Chief Compliance Officer & General Counsel
Stuart Madden Chief Scientific Officer
Chuck DeWildt Chief Commercial Officer & Senior Vice President
You’re viewing 5 of 8 executive team members. Get the full list »

Neurelis Board Members (12)

Name Representing Role Since
Alexander Kwit Neurelis Board Member 000 0000
Craig Chambliss Neurelis Co-Founder, Chief Executive Officer, Board Member & President 000 0000
David Hale Self Co-Founder & Board Member 000 0000
Huaizheng Peng Ph.D Self Board Member 000 0000
Kevin Li Ph.D Neurelis Chairman 000 0000
You’re viewing 5 of 12 board members. Get the full list »

Neurelis Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Neurelis Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Cormorant Asset Management Hedge Fund Minority 000 0000 000000 0
Decheng Capital Venture Capital Minority 000 0000 000000 0
Philos & Partners Asset Manager Minority 000 0000 000000 0
China Medical System Corporation Minority 000 0000 000000 0
HBM Healthcare Investments Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »

Neurelis Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 000000000000 03-Dec-2018 000000000000000000 Drug Delivery 00000 000000000
To view Neurelis’s complete acquisitions history, request access »